If you are looking to make some serious investing returns, look no further than TipRanks’ recently revamped stock screener. The screener enables you to filter results by Best Analyst Consensus and Best Analyst Price Target. Here we searched for stocks of all sectors, with a ‘Strong Buy’ consensus rating and upside potential of at least over 20%. Bear in mind that the best analysts are those with a proven track record of success with their stock picking selections. You will see below how all the analysts referred to here have a four or five star rating on TipRanks.

To find stocks with the most promising upside potential, simply order the results by analyst price target. This displays the stocks with the biggest upside potential first, allowing you to quickly cherry-pick the best stocks out there according to the Street.

Let’s dive in to five of the standout stocks now:

1. Micron (NASDAQ:MU)

Red-hot chip stock Micron is primed for massive gains. This is according to top Rosenblatt Securities analyst Hans Mosesmann (Profile & Recommendations). He believes MU is enjoying “healthy, broad-based and sustainable” momentum and writes: “Net/net: Micron is generating roughly $10 billion in FCF [free cash flow] per year, has initiated a $10 billion repurchase program, and is executing near-flawlessly in a memory market that is structurally changed within a rationally oligopolistic industry.” Boom!

He ramped up his price target from $115 to $120 (110% upside potential) in June following Micron’s stellar fiscal Q3 earnings results. “Yes, another one of those beat-and-raises and we expect consensus numbers to move up” Mosesmann wrote at the time. Most encouragingly, he spies big potential for MU in the fast-growing world of AI. This is because AI servers require six times the DRAM of today’s servers.

2. Galmed Pharmaceuticals (NASDAQ:GLMD)

This cutting-edge biopharma is developing Aramchol, a novel, once-daily, oral therapy to treat liver diseases. Galmed’s main focus right now is on treating non-alcoholic steatohepatitis (NASH), a major contributor to liver disease, affecting roughly 50 million people in the U.S. and EU5.

Already, the buzz is beginning with prices exploding by 134% in the last three months. This was on the back of extremely impressive Phase 2b ARREST trial results for lead drug candidate Aramchol. The drug demonstrated a squeaky-clean safety profile with positive efficacy across numerous endpoints.

Even factoring in recent gains, GLMD still offers plenty of upside ahead say top analysts. Indeed, we can see that the $36 average analyst price target translates into 145% upside from current levels. Word on the Street us that the company remains undervalued in relation to NASH space peers.

“Our price target increases to $30, from $14, implying a market capitalization of $450M, which may be viewed as “conservative” given the rise in valuations of others in the space, including Madrigal (MDGL – NR) which also completed a P2 study (smaller and shorter trial than Galmed too)” commented top Maxim analyst Jason McCarthy (Profile & Recommendations).

He added: “Aramchol is now one of the most clinically advanced NASH assets in the space with “good” data, which to us also could imply a scarcity value as well.”

3. Resonant (NASDAQ:RESN)

Small-cap tech stock Resonant is a designer of filters for radio frequency (RF) front-ends for smartphones. This is basically the circuitry in mobile phones for analog signal processing. And the stock is on the cusp of big growth according to the Street.

Five-star Loop Capital analyst Cody Acree (Profile & Recommendations) sees RESN exploding by a whopping 107%. He has initiated coverage with a Buy rating and $11 price target. “We believe the company continues to make significant fundamental customer and design win progress that should begin delivering material recurring royalties through the remainder of 2018”, writes Acree.

Specifically, he is a fan of the company’s unique Infinite Synthesized Network platform technology. This is “a software-based, high-precision modeling approach that is able to produce real-world testable results in a completed design”, explains Acree. Customers can now eliminate software design flaws before wafer production begins.

The best part is that this should prove much more “attractive to the market than the traditional method of running multiple physical iterations through a wafer fab”. Indeed, RESN boasts four recent Buy ratings from the Street. These analysts have an average price target of $8.25 (55% upside potential). View RESN Price Target & Analyst Rating Details

4. Akebia Therapeutics (NASDAQ:AKBA)

Keep a close eye on kidney biopharma Akebia Therapeutics. The company has just announced plans to merge with Keryx Biopharma. Keryx’s Auryxia is the only oral treatment option available today developed and approved specifically for adults living with iron deficiency anemia. Meanwhile Akebia is developing its own anemia drug called vadadustat.

Top 100 analyst Christopher Raymond (Profile & Recommendations) approves of the deal: Auryxia “has not just turned a corner, but is really on quite a roll, both in terms of the drug’s perception and its market share dynamics.” He has just boosted his price target from $20 to $22 (110% upside potential).

Raymond spies a “significant opportunity” to pick up Akebia before the drug’s near-term share gains and the “real potential of a nephrology powerhouse with both Auryxia and vadadustat, become more apparent.” Indeed, Akebia has received three buy ratings from top analysts in the last three months. This is with a $22 average analyst price target. View AKBA Price Target & Analyst Rating Details

5. Adesto (NASDAQ:IOTS)

If you are looking for a cheap stock heading for the big time, Adesto may well fit the bill. Adesto Technologies sells low power, specialty memory solutions for Internet of Things devices. This includes controllers, sensors, radios, and memory. Most encouragingly, we can see that a Top 50 analyst has a $12 price target on the stock (94% upside potential).

Needham’s Rajvindra Gill (Profile & Recommendations) recently reiterated his “Strong Buy” rating on IOTS, praising the company’s “market leading” technology. Adesto’s design win annual revenue run-rate potential grew 85% year-over-year in 2017, including a record 400-plus wins last year. “Adesto carries positive momentum into 2018,” Gill writes.

Plus the company has just snapped up S3 Semiconductors, and is in the process of acquiring networking pioneer Echelon. “We believe the merged companies have the R&D team and roadmaps to create highly differentiated solutions for targeted Industrial IoT customers” comments Canaccord Genuity’s Michael Walkley (Profile & Recommendations). He has just initiated IOTS with a Buy rating and $11 price target.

Find your own ‘Strong Buy’ ideas with the Stock Screener

The upgraded screener includes many exciting new datasets enabling you to refine your search options and find high-quality investing inspiration more easily and efficiently than ever before. New filters include Analyst Price Target and Best Analyst Price Target. Use these filters to find the Street’s most promising ‘Strong Buy’ stocks with over 20% upside potential from the current share price.

Go the stock screener now<<